TOKYO/JAKARTA -- Pharmaceutical companies have largely been unwilling to develop vaccines and treatment for dengue fever, citing small demand due to the disease primarily occurring in emerging nations. But as the disease spreads, with the current outbreak in Japan already topping 100 cases, major drugmakers are now rushing to tackle the threat.
A familiar foe
